FDA approves Invokana to treat type 2 diabetes
First in a new class of diabetes drugs FDA NEWS RELEASE: 29/3/2013 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm
Leggi
European Medicines Agency recommends restricting use of cilostazol-containing medicines
22 March 2013 - EMA/98571/2013 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Cilostazol-containing_medicines/human_referral_000338.jsp&mid=WC0b01ac05805c516f
Leggi
Comunicato Stampa EMA sull’uso concomitante di medicinali che agiscono sul sistema renina – angiotensina (RAS) (17/05/2013)
http://www.agenziafarmaco.gov.it/sites/default/files/RAS-acting_agents_-_comunicato%20EMA%5B1%5D.pdf
Leggi
Comunicazione AIFA
Precisazione AIFA su Incretine 20/05/2013 http://www.agenziafarmaco.gov.it/it/content/precisazione-aifa-su-incretine-0
Leggi
European Medicines Agency – Outcome of review of new safety data on insulin glargine
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2013 EMA/329790/2013 http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500143823
Leggi
ADA/EASD Recommendations for Clinicians and People with Diabetes Concerning the Use of Incretin Therapy and Pancreatic Disease
27 giugno 2013 http://easd.org/index.php?option=com_content&view=article&id=172
Leggi
FDA Drug Safety Communication: FDA requires label warnings to prohibit sharing of multi-dose diabetes pen devices among patients
25/02/2015 http://www.fda.gov/Drugs/DrugSafety/ucm435271.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery
Leggi
The Committee for Medicinal Products for Human Use (CHMP) recommended the addition of a new formulation to the marketing authorisation of Optisulin (insulin glargine) and a change of its invented name to Toujeo.
The new formulation of Toujeo is a higher-strength insulin (300 units/ml) 26/02/2015 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000309/smops/Positive/human_smop_000789.jsp&mid=WC0b01ac058001d127
Leggi
The Diabetic HFpEF Phenotype: Is it Real and is it Worth Targeting Therapeutically?
Lindman BR
Circulation. Pub. online January 4, 2017
Leggi
Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients with Heart Failure and Preserved Ejection Fraction. A Report from the Irbesartan in Heart Failure with Preserved Ejection Fraction Trial (I-
Kristensen SL, Mogensen UM, Jhund PS, et al.
Circulation. Pub. online January 4, 2017
Leggi